Table 2 Summary of clinical trials of main targeted agents
Agent | Targets | Results | Cancer type | References |
|---|---|---|---|---|
Cetuximab | EGFR | mPFS (Placebo vs. Cetuximab): 2.0 months vs. 2.9 months mOS (Placebo vs. Cetuximab): 3.0 months vs. 5.1 months | EAC | |
Nimotuzumab | EGFR | mPFS: 13.9 months mOS: 9 months | ESCC | |
Gefitinib | EGFR | mPFS: 2.2 months mOS: 6.1 months | ESCC | |
Icotinib | EGFR | mPFS: 1.7 months mOS: 3.73 months | ESCC | |
Trastuzumab | HER2 | mPFS: 7.8 months mOS: 16 months | EAC | |
Lapatinib | HER3 | PFS: 6.0 months OS: 12.2 months | ESCC | |
Bevacizumab | VEGF/VEGFR | 3-year overall survival (chemotherapy alone group vs. bevacizumab group): 48.1% vs. 50.3% | EAC | |
Ramucirumab | VEGF/VEGFR | mPFS: 5.1 months mOS: 5.2 months | GEJ | |
Endostar and Chemotherapy | VEGF/VEGFR | PFS > 8 months | ESCC | |
Sunitinib | VEGF/VEGFR | mPFS (Sunitinib+FOLFIRI vs. Sunitinib+Placebo): 3.5 months vs. 3.3 months | GEJ | |
Sorafenib | VEGF/VEGFR | mPFS: 5.8 months mOS: 13.6 months | GEJ | |
Apatinib | VEGF/VEGFR | PFS: 3.8 months OS: 6.96 months | ESCC | |
Anlotinib | VEGF/VEGFR | mPFS (Placebo vs. Anlotinib):1.4 months vs. 3.0 months Disease control rates (DCR): 38.1% | ESCC | |
Pembrolizumab | PD-1/PD-L1 | mOS: 5.8 months Overall remission rate (ORR): 14.3% vs. 5.2% | ESCC/EAC | |
Camrelizumab | PD-1/PD-L1 | PFS: 2.0 months OS: 8.0 months | ESCC | |
Ipilimumab and Nivolumab | PD-1/PD-L1 | mOS (Ipilimumab&Nivolumab vs. Nivolumab): 6.9 months vs. 5.0 months | EC |
